Today: 7 February 2026
Subscribe
Browse Category

Pharmaceuticals News 28 January 2026 - 30 January 2026

AbbVie stock rises as ABBV heads into Feb. 4 earnings; Botox price talks in focus

AbbVie stock rises as ABBV heads into Feb. 4 earnings; Botox price talks in focus

AbbVie shares rose about 1% Friday, closing near $222.73 ahead of its Feb. 4 earnings report and first 2026 guidance. Investors are watching Botox pricing risks after Medicare listed it for price negotiations, and new aesthetics data from Paris. The stock dropped 2.35% Wednesday, ending a five-day rally. Goldman Sachs kept a neutral rating with a $223 target.
30 January 2026
···
Eli Lilly stock barely budges after $1.93bn autoimmune pact; Trump touts six U.S. plants

Eli Lilly stock barely budges after $1.93bn autoimmune pact; Trump touts six U.S. plants

Eli Lilly shares closed up 0.03% at $1,024.14 after announcing new research deals in autoimmune disease and gene-editing for hearing loss. Repertoire Immune Medicines will receive $85 million upfront in a collaboration potentially worth $1.84 billion. Lilly also signed a gene-editing agreement with Seamless Therapeutics valued up to $1.12 billion. Investors await Feb. 4 earnings for updates on demand and supply.
30 January 2026
···
Olema Pharmaceuticals (OLMA) stock jumps 6% in a weak market — what to watch next

Olema Pharmaceuticals (OLMA) stock jumps 6% in a weak market — what to watch next

Olema Pharmaceuticals shares rose 5.8% to $25.99 Thursday afternoon, adding about $127 million in market value as broader indexes fell. Trading volume reached 926,000 shares. No new company news emerged, but traders are watching for Olema’s March update and progress on its late-stage palazestrant trial. The company reported over $500 million in cash and equivalents as of Dec. 31, 2025.
29 January 2026
··
Johnson & Johnson stock price drifts after record-area run as Morgan Stanley upgrade keeps spotlight on new drugs

Johnson & Johnson stock price drifts after record-area run as Morgan Stanley upgrade keeps spotlight on new drugs

Johnson & Johnson shares slipped 0.1% to $227.43 by midday Thursday after peaking near record highs, following a Morgan Stanley upgrade and a price target hike to $262. The FDA approved a new Darzalex Faspro combination for multiple myeloma on Jan. 27. CEO Joaquin Duato’s spouse sold 100,000 shares last week, SEC filings show. J&J forecasts 2026 sales up to $100.5 billion and EPS up to $11.63.
29 January 2026
··
Eli Lilly stock price today: LLY rises on $1.93 billion Repertoire deal as earnings near

Eli Lilly stock price today: LLY rises on $1.93 billion Repertoire deal as earnings near

Eli Lilly shares rose 0.5% Thursday after Repertoire Immune Medicines announced a partnership with the company worth up to $1.93 billion. The deal follows Lilly’s $1.12 billion gene-editing agreement targeting hearing loss. Investors are also watching for Medicare’s plan to include Trulicity in upcoming price negotiations. Lilly’s earnings report is expected Feb. 4.
29 January 2026
····
GSK shares tick higher after Citi’s neutral call as Feb. 4 results loom

GSK shares tick higher after Citi’s neutral call as Feb. 4 results loom

GSK shares rose 0.34% to 1,823.75 pence early Thursday in London after a 2.42% drop Wednesday. Citi began coverage with a Neutral rating and a 1,900p target, noting pipeline improvements but warning on valuation. Investors await GSK’s Feb. 4 earnings for updates on vaccines, HIV treatments, and 2026 guidance. GSK’s RSV vaccine Arexvy recently gained EU approval for adults 18 and older.
29 January 2026
··
Johnson & Johnson stock price rises as Morgan Stanley upgrades JNJ and FDA clears new Darzalex regimen

Johnson & Johnson stock price rises as Morgan Stanley upgrades JNJ and FDA clears new Darzalex regimen

Johnson & Johnson shares rose 1.5% to $227.72 Wednesday after Morgan Stanley upgraded the stock and raised its price target to $262. The FDA approved expanded use of J&J’s Darzalex Faspro for newly diagnosed multiple myeloma patients ineligible for stem cell transplants. A regulatory filing showed CEO Joaquin Duato’s spouse sold about $22 million in shares.
29 January 2026
··
Johnson & Johnson stock rises on Darzalex Faspro FDA nod as traders size up drug-pricing risks

Johnson & Johnson stock rises on Darzalex Faspro FDA nod as traders size up drug-pricing risks

Johnson & Johnson shares rose 1.2% to $227.06 after the FDA approved Darzalex Faspro for use with the VRd regimen in newly diagnosed multiple myeloma patients ineligible for stem cell transplant. The approval is based on the CEPHEUS trial, which showed improved outcomes. The move comes as Medicare named 15 drugs for future price negotiations, pressuring the sector.
28 January 2026
··
Pfizer stock drops as Medicare puts Xeljanz on 2028 price-talk list, earnings next week

Pfizer stock drops as Medicare puts Xeljanz on 2028 price-talk list, earnings next week

Pfizer shares fell 1.8% to $26.02 after U.S. Medicare included Xeljanz in its upcoming drug price negotiations, set to begin in 2026 with prices effective in 2028. The Centers for Medicare & Medicaid Services named 15 drugs for talks, and companies must decide by February 28 whether to participate. Investors are awaiting Pfizer’s February 3 earnings for updates on pricing risks.
28 January 2026
······
Eli Lilly stock drops today: LLY slides after $1.12 billion gene-editing deal and Medicare pricing signal

Eli Lilly stock drops today: LLY slides after $1.12 billion gene-editing deal and Medicare pricing signal

Eli Lilly shares fell 2.4% to $1,015.05 Wednesday after the company announced a gene-editing deal with Seamless Therapeutics worth up to $1.12 billion. The U.S. government included Lilly’s Trulicity in the next round of Medicare drug-price negotiations, raising pricing concerns. Obesity drug rivals increased ad spending, intensifying competition.
28 January 2026
···
Pfizer stock dips after Xeljanz lands on Medicare price-talk list, with earnings looming

Pfizer stock dips after Xeljanz lands on Medicare price-talk list, with earnings looming

Pfizer shares fell 1.7% to $26.06 after CMS selected its arthritis drug Xeljanz for Medicare price negotiations, with new prices set for 2028. Xeljanz accounted for about $1.01 billion in Medicare spending in the latest period. Investors await Pfizer’s Feb. 3 quarterly results and a Feb. 28 CMS deadline for drugmakers to sign participation agreements.
28 January 2026
···
GSK share price slips in London as Arexvy EU expansion sinks in; earnings next week in focus

GSK share price slips in London as Arexvy EU expansion sinks in; earnings next week in focus

GSK shares dropped 1.8% to 1,828.5 pence by mid-morning Wednesday in London, reversing gains from earlier in the week. The decline followed news that the European Commission expanded approval of GSK’s RSV vaccine Arexvy to all adults 18 and older. Pfizer also secured similar approval for its RSV shot. Investors await guidance from European health agencies and GSK’s earnings report on February 4.
28 January 2026
···
Why Gilead stock hit a fresh 52-week high as Medicare targets Biktarvy and earnings loom

Why Gilead stock hit a fresh 52-week high as Medicare targets Biktarvy and earnings loom

Gilead Sciences shares rose 2.3% to $140.97 Tuesday, hitting a 52-week high after Medicare named its HIV drug Biktarvy for price negotiations starting in 2028. Trading volume topped 10.5 million shares. CEO Daniel O’Day sold 115,640 shares last week under a pre-set plan. Gilead will report fourth-quarter and full-year results after markets close on Feb. 10.
28 January 2026
···
Johnson & Johnson stock climbs after fresh FDA Darzalex Faspro nod — what investors watch next

Johnson & Johnson stock climbs after fresh FDA Darzalex Faspro nod — what investors watch next

Johnson & Johnson shares rose 1.3% Tuesday after the FDA approved a Darzalex Faspro combination for newly diagnosed multiple myeloma patients ineligible for stem-cell transplants. The S&P 500 closed at a record high, while healthcare stocks broadly fell after a Medicare payment proposal. The U.S. also named 15 drugs for future Medicare price negotiations, increasing pressure on big pharma.
28 January 2026
···
1 … 3 4 5 6 7 … 34

Stock Market Today

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

7 February 2026
COPENHAGEN, February 7, 2026, 23:19 CET — Market closed. Novo Nordisk A/S Class B shares will be back in focus when trading resumes on Monday after telehealth firm Hims & Hers said it would stop offering access to a $49 compounded version of Novo’s Wegovy pill following U.S. regulatory warnings. Novo’s Copenhagen-listed shares ended Friday at 295.50 crowns, up 5.3%, according to Reuters market data. (Reuters) Why it matters now: the $49 offer put a fresh spotlight on how quickly cheaper, unapproved copies can spread in the fast-growing obesity-drug market — and how hard it may be for drugmakers to
Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

7 February 2026
Linde plc shares fell 2.5% to $448.24 Friday after reporting Q4 sales up 6% to $8.76 billion and adjusted EPS of $4.20. The company guided 2026 adjusted EPS to $17.40–$17.90, below analyst consensus. JPMorgan downgraded the stock, while Morgan Stanley and UBS raised price targets. Linde repurchased $1.4 billion in shares in Q4 and returned $7.4 billion to shareholders in 2025.
Go toTop